Retinal optical coherence tomography and magnetic resonance imaging in neuromyelitis optica spectrum disorders and MOG-antibody associated disorders: an updated review

References

• Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176:149–164.
   PubMed Web of Science ®Google Scholar
• Borisow N, Mori M, Kuwabara S, et al. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol. 2018;9:888.
   PubMedGoogle Scholar
• Jarius S, Paul F, Franciotta D, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol. 2008;4:202–214.
   PubMedGoogle Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189.
   PubMed Web of Science ®Google Scholar
• Papais-Alvarenga RM, Carellos SC, Alvarenga MP, et al. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol. 2008;126(1):12–16.
   PubMedGoogle Scholar
• Misu T, Fujihara K, Nakashima I, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005;65(9):1479–1482.
   PubMed Web of Science ®Google Scholar
• Kanbayashi T, Shimohata T, Nakashima I, et al. Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol. 2009;66(12):1563–1566.
   PubMedGoogle Scholar
• Popescu BFG, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology. 2011;76(14):1229–1237.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Nakamura T, Hashimoto K, et al. Hypothermia, hypotension, hypersomnia, and obesity associated with hypothalamic lesions in a patient positive for the anti-aquaporin 4 antibody: a case report and literature review. Arch Neurol. 2012;69(10):1355–1359.
   PubMedGoogle Scholar
• Shosha E, Dubey D, Palace J, et al. Area postrema syndrome: frequency, criteria, and severity in AQP4-IgG-positive NMOSD. Neurology. 2018;91(17):E1642–E1651.
   PubMedGoogle Scholar
• Kremer L, Mealy M, Jacob A, et al. Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler J. 2014;20(7):843–847.
   PubMed Web of Science ®Google Scholar
• Kim W, Kim SH, Hyun Lee S, et al. Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. Mult Scler J. 2011;17(9):1107–1112.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Miyazawa I, Misu T, et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry. 2008;79(9):1075–1078.
   PubMed Web of Science ®Google Scholar
• Paul F, Jarius S, Aktas O, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007;4(4):669–674.
   Google Scholar
• Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9(1):14.
   PubMedGoogle Scholar
• Zekeridou A, Lennon VA. Aquaporin-4 autoimmunity. Neurol Neuroimmunol NeuroInflammation. 2015;2(4):e110.
   Google Scholar
• Metz I, Beißbarth T, Ellenberger D, et al. Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. Neurol Neuroimmunol NeuroInflammation. 2016;3(2):e204.
   Google Scholar
• Reindl M, Schanda K, Woodhall M, et al. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol neuroinflammation. 2020;7(2):e674.
   Web of Science ®Google Scholar
• Schanda K, Peschl P, Lerch M, et al. Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases. Neurol Neuroimmunol neuroinflammation. 2021;8(5):e1027.
   PubMedGoogle Scholar
• Dale RC, Tantsis EM, Merheb V, et al. Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol NeuroInflammation. 2014;1(1):e12.
   PubMedGoogle Scholar
• Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibodypositive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474–481.
   PubMed Web of Science ®Google Scholar
• Kim SM, Woodhall MR, Kim JS, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol NeuroInflammation. 2015;2(6):e163.
   Google Scholar
• Waters P, Woodhall M, O’Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol NeuroInflammation. 2015;2(3):e89.
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016;13(1):279.
   Google Scholar
• Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280.
   Google Scholar
• Hamid SHM, Whittam D, Mutch K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017;264(10):2088–2094.
   PubMed Web of Science ®Google Scholar
• Chalmoukou K, Alexopoulos H, Akrivou S, et al. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol NeuroInflammation. 2015;2(4):e131.
   PubMedGoogle Scholar
• Reindl M, Rostasy K. MOG antibody-associated diseases. Neurol Neuroimmunol NeuroInflammation. 2015;2(1):e60.
   Google Scholar
• Bruijstens AL, Wong YYM, van Pelt DE, et al. HLA association in MOG-IgG- and AQP4-IgG-related disorders of the CNS in the Dutch population. Neurol Neuroimmunol neuroinflammation. 2020;7(3):e702.
   Google Scholar
• Kim H, Lee EJ, Kim S, et al. Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol Neuroimmunol neuroinflammation. 2020;7(3):e708.
   Google Scholar
• Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol NeuroInflammation. 2015;2(1):e62.
   Google Scholar
• Sepúlveda M, Armangué T, Sola-Valls N, et al. Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol NeuroInflammation. 2016;3(3):e225.
   PubMedGoogle Scholar
• Spadaro M, Gerdes LA, Krumbholz M, et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol NeuroInflammation. 2016;3(5):e257.
   PubMedGoogle Scholar
• Ogawa R, Nakashima I, Takahashi T, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol NeuroInflammation. 2017;4(2):e322.
   PubMedGoogle Scholar
• Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15(1):134.
   Google Scholar
• Narayan R, Simpson A, Fritsche K, et al. MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018;25:66–72.
   PubMed Web of Science ®Google Scholar
• Vazquez Do Campo R, Stephens A, Marin Collazo IV, et al. MOG antibodies in combined central and peripheral demyelination syndromes. Neurol Neuroimmunol NeuroInflammation. 2018;5(6):e503.
   PubMedGoogle Scholar
• Cobo-Calvo A, Sepúlveda M, Rollot F, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation. 2019;16(1):134.
   PubMedGoogle Scholar
• Hamid SHM, Whittam D, Saviour M, et al. Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol. 2018;75(1):65–71.
   PubMedGoogle Scholar
• Cobo-Calvo A, Ayrignac X, Kerschen P, et al. Cranial nerve involvement in patients with MOG antibody-associated disease. Neurol Neuroimmunol NeuroInflammation. 2019;6(2):e543.
   PubMedGoogle Scholar
• Matesanz S, Kotch C, Perrone C, et al. Expanding the MOG phenotype: brainstem encephalitis with punctate and curvilinear enhancement. Neurol Neuroimmunol neuroinflammation. 2019;6(6):e619.
   PubMedGoogle Scholar
• Rinaldi S, Davies A, Fehmi J, et al. Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders. Neurol Neuroimmunol neuroinflammation. 2020;8(1):e924.
   Google Scholar
• Alves Do Rego C, Collongues N. Neuromyelitis optica spectrum disorders: features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes. Rev Neurol (Paris). 2018;174(6):458–470.
   PubMedGoogle Scholar
• Fujihara K. Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol. 2019;32(3):385–394.
   PubMed Web of Science ®Google Scholar
• Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135(6):1834–1849.
   PubMedGoogle Scholar
• Schmidt F, Zimmermann H, Mikolajczak J, et al. Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2017;11:45–50.
   PubMed Web of Science ®Google Scholar
• Naismith RT, Tutlam NT, Xu J, et al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology. 2009;72(12):1077–1082.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Nakazawa T, Doi H, et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefe’s Arch Clin Exp Ophthalmol. 2010;248(12):1777–1785.
   PubMed Web of Science ®Google Scholar
• Monteiro MLR, Fernandes DB, Apóstolos-Pereira SL, et al. Quantification of retinal neural loss in patients with neuromyelitis optica and multiple sclerosis with or without optic neuritis using Fourier-domain optical coherence tomography. Investig Ophthalmol Vis Sci. 2012;53(7):3959–3966.
   PubMed Web of Science ®Google Scholar
• Bouyon M, Collongues N, Zéphir H, et al. Longitudinal follow-up of vision in a neuromyelitis optica cohort. Mult Scler J. 2013;19(10):1320–1322.
   PubMedGoogle Scholar
• Fernandes DB, Raza AS, Nogueira R, et al. Evaluation of Inner Retinal Layers in Patients with Multiple Sclerosis or Neuromyelitis Optica Using Optical Coherence Tomography. Ophthalmology. 2013;120(2):387–394.
   PubMed Web of Science ®Google Scholar
• Sotirchos ES, Saidha S, Byraiah G, et al. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology. 2013;80(15):1406–1414.
   PubMed Web of Science ®Google Scholar
• Bennett JL, de Seze J, Lana-Peixoto M, et al. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler J. 2015;21(6):678–688.
   PubMed Web of Science ®Google Scholar
• Outteryck O, Majed B, Defoort-Dhellemmes S, et al. A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis. Mult Scler. 2015;21(14):1781–1793.
   PubMedGoogle Scholar
• Akaishi T, Sato DK, Nakashima I, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatry. 2016;87(4):446–448.
   PubMed Web of Science ®Google Scholar
• Oertel FC, Kuchling J, Zimmermann H, et al. Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. Neurol Neuroimmunol NeuroInflammation. 2017;4(3):e334.
   Google Scholar
• Wang F, Liu Y, Duan Y, et al. Brain MRI abnormalities in neuromyelitis optica. Eur J Radiol. 2011;80(2):445–449.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84(11):1165–1173.
   Google Scholar
• Ramanathan S, Prelog K, Barnes EH, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler J. 2016;22(4):470–482.
   PubMed Web of Science ®Google Scholar
• Juenger V, Cooper G, Chien C, et al. Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders. Eur Radiol. European Radiology. 2020;30(9):5048–5058.
   PubMedGoogle Scholar
• Nakamura M, Miyazawa I, Fujihara K, et al. Preferential spinal central gray matter involvement in neuromyelitis optica: an MRI study. J Neurol. 2008;255(2):163–170.
   PubMed Web of Science ®Google Scholar
• Cassinotto C, Deramond H, Olindo S, et al. MRI of the spinal cord in neuromyelitis optica and recurrent longitudinal extensive myelitis. J Neuroradiol. 2009;36(4):199–205.
   PubMedGoogle Scholar
• Asgari N, Skejoe HPB, Lillevang ST, et al. Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study. BMC Neurol. 2013;13:33.
   Google Scholar
• Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485–1489.
   PubMed Web of Science ®Google Scholar
• Ciccarelli O, Cohen JA, Reingold SC, et al. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurol. 2019;18(2):185–197.
   PubMed Web of Science ®Google Scholar
• Pekcevik Y, Mitchell CH, Mealy MA, et al. Differentiating neuromyelitis optica from other causes of longitudinally extensive myelitison spinal magnetic resonance imaging. Mult Scler J. 2016;22(3):302–311.
   Google Scholar
• Chien C, Scheel M, Schmitz-Hübsch T, et al. Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity. Mult Scler J. 2019;25(14):1926–1936.
   PubMed Web of Science ®Google Scholar
• Dubey D, Pittock SJ, Krecke KN, et al. Clinical, Radiologic, and Prognostic Features of Myelitis Associated with Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurol. 2019;76(3):301–309.
   PubMed Web of Science ®Google Scholar
• Huh SY, Min JH, Kim W, et al. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult Scler J. 2014;20(6):695–704.
   PubMed Web of Science ®Google Scholar
• Wang KY, Chetta J, Bains P, et al. Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review. Br J Radiol. 2018;91(1086):20170690.
   Google Scholar
• Kim W, Kim SH, Huh SY, et al. Brain Abnormalities in Neuromyelitis Optica Spectrum Disorder. Mult Scler Int. 2012;2012:735486.
   PubMedGoogle Scholar
• Bichuetti DB, Rivero RLM, Oliveira DM, et al. Neuromyelitis optica: brain abnormalities in a Brazilian cohort. Arq Neuropsiquiatr. 2008;66(1):1–4.
   Google Scholar
• Chan KH, Tse CT, Chung CP, et al. Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol. 2011;68(11):1432–1439.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Weinshenker BG, Lucchinetti CF, et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006;63(7):964–968.
   PubMed Web of Science ®Google Scholar
• Kim W, Park MS, Lee SH, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler J. 2010;16(10):1229–1236.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Misu T, Fujihara K, et al. Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler. 2009;15(6):695–700.
   PubMedGoogle Scholar
• Jurynczyk M, Geraldes R, Probert F, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain. 2017;140(3):617–627.
   PubMedGoogle Scholar
• Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2018;90(21):e1858–e1869.
   PubMed Web of Science ®Google Scholar
• Kleiter I, Gahlen A, Borisow N, et al. Apheresis therapies for NMOSD attacks A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol NeuroInflammation. 2018;5(6):e504.
   Google Scholar
• Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol NeuroInflammation. 2019;6(4):e572.
   PubMedGoogle Scholar
• Jarius S, Paul F, Weinshenker BG, et al. Neuromyelitis optica. Nat Rev Dis Prim. 2020;6(1):85.
   Google Scholar
• Kim SH, Jang H, Park NY, et al. Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies. Neurol Neuroimmunol neuroinflammation. 2021;8(2):e947.
   Google Scholar
• Li S, Ren H, Xu Y, et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study. Neurol Neuroimmunol neuroinflammation. 2020;7(3):e705.
   Google Scholar
• Whittam DH, Karthikeayan V, Gibbons E, et al. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol. 2020;267(12):3565–3577.
   PubMedGoogle Scholar
• Oberwahrenbrock T, Traber GL, Lukas S, et al. Multicenter reliability of semiautomatic retinal layer segmentation using OCT. Neurol Neuroimmunol Neuroinflammation. 2018;5(3):e449.
   PubMedGoogle Scholar
• Zimmermann H, Oberwahrenbrock T, Brandt AU, et al. Optical coherence tomography for retinal imaging in multiple sclerosis. Degener Neurol Neuromuscul Dis. 2014;4:153–162.
   PubMedGoogle Scholar
• Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science. 1991;254(5035):1178–1181.
   PubMed Web of Science ®Google Scholar
• Jindahra P, Hedges TR, Mendoza-Santiesteban CE, et al. Optical coherence tomography of the retina: applications in neurology. Curr Opin Neurol. 2010;23(1):16–23.
   PubMed Web of Science ®Google Scholar
• Wojtkowski M, Leitgeb R, Kowalczyk A, et al. In vivo human retinal imaging by Fourier domain optical coherence tomography. J Biomed Opt. 2002;7(3):457–463.
   Google Scholar
• Patel NB, Wheat JL, Rodriguez A, et al. Agreement between Retinal Nerve Fiber Layer Measures from Spectralis and Cirrus Spectral Domain OCT. Optom Vis Sci. 2012;89(5):E652–E666.
   PubMedGoogle Scholar
• Yaqoob Z, Wu J, Yang C. Spectral domain optical coherence tomography: a better OCT imaging strategy. Biotechniques. 2005;39(6 Suppl):S6–S13.
   Google Scholar
• Schematic Figure – retina (Creative Commons License) – neurodiagnostics Laboratory [Internet]. [cited 2021 Jun 29]. Available from: http://neurodial.de/2017/08/25/schematic-figure-retina-creative-commons-license/
   Google Scholar
• Schematic Figure – macular OCT with Intraretinal Layers (Creative Commons License) – neurodiagnostics Laboratory. [Internet]. [cited 2021 Jun 29]. Available from: http://neurodial.de/2017/08/25/schematic-figure-macular-oct-with-intraretinal-layers/.
   Google Scholar
• Tewarie P, Balk L, Costello F, et al. The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One. 2012;7(4):e34823.
   PubMedGoogle Scholar
• Schippling S, Balk LJ, Costello F, et al. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Mult Scler J. 2015;21(2):163–170.
   PubMed Web of Science ®Google Scholar
• Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2016;86(24):2303–2309.
   PubMed Web of Science ®Google Scholar
• Aytulun A, Cruz-Herranz A, Aktas O, et al. The APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. Neurology. 2021;97(2):68–79.
   PubMedGoogle Scholar
• Syc SB, Saidha S, Newsome SD, et al. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain. 2012;135(2):521–533.
   PubMedGoogle Scholar
• Kafieh R, Rabbani H, Kermani S. A Review of Algorithms for Segmentation of Optical Coherence Tomography from Retina. J Med Signals Sens. 2013;3(1):45–60.
   PubMedGoogle Scholar
• Motamedi S, Gawlik K, Ayadi N, et al. Normative Data and Minimally Detectable Change for Inner Retinal Layer Thicknesses Using a Semi-automated OCT Image Segmentation Pipeline. Front Neurol. 2019;10:1117.
   PubMedGoogle Scholar
• Schneider E, Zimmermann H, Oberwahrenbrock T, et al. Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS One. 2013;8(6):e66151.
   Google Scholar
• Kaufhold F, Zimmermann H, Schneider E, et al. Optic Neuritis Is Associated with Inner Nuclear Layer Thickening and Microcystic Macular Edema Independently of Multiple Sclerosis. PLoS One. 2013;8(8):e71145.
   Google Scholar
• Pache F, Zimmermann H, Mikolajczak J, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016;13(1):282.
   Google Scholar
• Oertel FC, Zimmermann H, Paul F, et al. Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy. EPMA J. 2018;9(1):21–33.
   PubMed Web of Science ®Google Scholar
• Filippatou AG, Mukharesh L, Saidha S, et al. AQP4-IgG and MOG-IgG Related Optic Neuritis—Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: a Systematic Review and Meta-Analysis. Front Neurol. 2020;11:540156.
   PubMedGoogle Scholar
• Oberwahrenbrock T, Weinhold M, Mikolajczak J, et al. Reliability of intra-retinal layer thickness estimates. PLoS One. 2015;10(9):e0137316.
   PubMedGoogle Scholar
• Petzold A, Wattjes MP, Costello F, et al. The investigation of acute optic neuritis: a review and proposed protocol. Nat Rev Neurol. 2014;10(8):447–458.
   PubMed Web of Science ®Google Scholar
• Burkholder BM, Osborne B, Loguidice MJ, et al. Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol. 2009;66(11):1366–1372.
   PubMedGoogle Scholar
• Costello F, Pan YI, Yeh EA, et al. The temporal evolution of structural and functional measures after acute optic neuritis. J Neurol Neurosurg Psychiatry. 2015;86(12):1369–1373.
   PubMedGoogle Scholar
• Vecino E, Rodriguez FD, Ruzafa N, et al. Glia-neuron interactions in the mammalian retina. Prog Retin Eye Res. 2016;51:1–40.
   PubMed Web of Science ®Google Scholar
• Bringmann A, Pannicke T, Grosche J, et al. Müller cells in the healthy and diseased retina. Prog Retin Eye Res. 2006;25(4):397–424.
   PubMed Web of Science ®Google Scholar
• Goodyear MJ, Crewther SG, Junghans BM. A role for aquaporin-4 in fluid regulation in the inner retina. Vis Neurosci. 2009;26(2):159–165.
   PubMedGoogle Scholar
• Reichenbach A, Bringmann A. New functions of Müller cells. Glia. 2013;61(5):651–678.
   Google Scholar
• Felix CM, Levin MH, Verkman AS. Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G. J Neuroinflammation. Journal of Neuroinflammation. 2016;13(1):275.
   Google Scholar
• Gelfand JM, Cree BA, Nolan R, et al. Microcystic inner nuclear layer abnormalities and neuromyelitis optica. JAMA Neurol. 2013;70(5):629–633.
   PubMed Web of Science ®Google Scholar
• Brandt AU, Oberwahrenbrock T, Kadas EM, et al. Dynamic formation of macular microcysts independent of vitreous traction changes. Neurology. 2014:83(1):73–77.
   Google Scholar
• Khanna S, Sharma A, Huecker J, et al. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuro-Ophthalmol. 2012;32(3):216–220.
   PubMed Web of Science ®Google Scholar
• Storoni M, Davagnanam I, Radon M, et al. Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system. J Neuro-Ophthalmol. 2013;33(2):123–127.
   PubMedGoogle Scholar
• Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Myelin Oligodendrocyte Glycoprotein Antibody–Positive Optic Neuritis: clinical Characteristics, Radiologic Clues, and Outcome. Am J Ophthalmol. 2018;195:8–15.
   PubMed Web of Science ®Google Scholar
• Akaishi T, Nakashima I, Takeshita T, et al. Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. J Neuroimmunol. 2016;293:28–33.
   PubMed Web of Science ®Google Scholar
• Akaishi T, Kaneko K, Himori N, et al. Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica. J Neuroimmunol. 2017;313:10–15.
   PubMedGoogle Scholar
• Lotan I, Oertel FC, Chien C, et al. Practical recognition tools of immunoglobulin G serum antibodies against the myelin oligodendrocyte glycoprotein-positive optic neuritis and its clinical implications. Clin Exp Neuroimmunol. 2021;12(1):42–53.
   Google Scholar
• Ramanathan S, Reddel SW, Henderson A, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol NeuroInflammation. 2014;1(4):e40.
   Google Scholar
• Biotti D, Bonneville F, Tournaire E, et al. Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. J Neurol. 2017;264(10):2173–2175.
   PubMed Web of Science ®Google Scholar
• Zhou L, Huang Y, Li H, et al. MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients. J Neuroimmunol. 2017;305:19–28.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Tan S, Chan TCY, et al. Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients. Br J Ophthalmol. 2018;102(10):1372–1377.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89(2):127–137.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhou H, Wang J, et al. The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis. J Neurol Sci. 2019;396:225–231.
   PubMed Web of Science ®Google Scholar
• Sotirchos ES, Filippatou A, Fitzgerald KC, et al. Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. Mult Scler J. 2020;26(11):1360–1371.
   PubMedGoogle Scholar
• Soelberg K, Specovius S, Zimmermann HG, et al. Optical coherence tomography in acute optic neuritis: a population-based study. Acta Neurol Scand. 2018;138(6):566–573.
   PubMedGoogle Scholar
• Pawlitzki M, Horbrügger M, Loewe K, et al. MS optic neuritis-induced long-term structural changes within the visual pathway. Neurol Neuroimmunol neuroinflammation. 2020;7(2):e665.
   PubMedGoogle Scholar
• Lotan I, Brody J, Hellmann MA, et al. Myelin oligodendrocyte glycoprotein-positive optic neuritis masquerading as pseudotumor cerebri at presentation. J Neurol. 2018;265(9):1985–1988.
   PubMedGoogle Scholar
• Srikajon J, Siritho S, Ngamsombat C, et al. Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis. Mult Scler J - Exp Transl Clin. 2018;4(3):205521731879119.
   Google Scholar
• Zhang X, Yu H, Zhang Y, et al. The application of RNFL thickness detection in early differential diagnosis among various types of idiopathic optic neuritis. J Clin Neurosci. 2018;55:82–85.
   PubMedGoogle Scholar
• Shen T, You Y, Arunachalam S, et al. Differing Structural and Functional Patterns of Optic Nerve Damage in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Ophthalmology. 2019;126(3):445–453.
   PubMed Web of Science ®Google Scholar
• You Y, Zhu L, Zhang T, et al. Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G–Positive Neuromyelitis Optica Spectrum Disorder. Ophthalmology. 2019;126(6):801–810.
   PubMedGoogle Scholar
• Zhao G, Chen Q, Huang Y, et al. Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China. J Neurol. 2018;265(1):33–40.
   PubMed Web of Science ®Google Scholar
• Oertel FC, Specovius S, Zimmermann HG, et al.Retinal optical coherence tomography in neuromyelitis optica. Neurol Neuroimmunol neuroinflammation.2021;8(6):e1068
   PubMedGoogle Scholar
• Lim YM, Pyun SY, Lim HT, et al. First-ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis. Neurol Sci. 2014;35(5):781–783.
   PubMed Web of Science ®Google Scholar
• Tian G, Li Z, Zhao G, et al. Evaluation of Retinal Nerve Fiber Layer and Ganglion Cell Complex in Patients with Optic Neuritis or Neuromyelitis Optica Spectrum Disorders Using Optical Coherence Tomography in a Chinese Cohort. J Ophthalmol. 2015;2015:832784.
   PubMedGoogle Scholar
• Hokari M, Yokoseki A, Arakawa M, et al. Clinicopathological features in anterior visual pathway in neuromyelitis optica. Ann Neurol. 2016;79(4):605–624.
   PubMed Web of Science ®Google Scholar
• Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, et al. Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2016;9(5):436–440.
   PubMedGoogle Scholar
• Stiebel-Kalish H, Lotan I, Brody J, et al. Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study. PLoS One. 2017;12(1):e170847.
   PubMedGoogle Scholar
• Mekhasingharak N, Laowanapiban P, Siritho S, et al. Optical coherence tomography in central nervous system demyelinating diseases related optic neuritis. Int J Ophthalmol. 2018;11(10):1649–1656.
   Google Scholar
• Pandit L, Mustafa S, Nakashima I, et al. MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response. Mult Scler J - Exp Transl Clin. 2018;4(3):2055217318787829.
   Google Scholar
• Bock M, Brandt AU, Dörr J, et al. Patterns of retinal nerve fiber layer loss in multiple sclerosis patients with or without optic neuritis and glaucoma patients. Clin Neurol Neurosurg. 2010;112(8):647–652.
   PubMed Web of Science ®Google Scholar
• Havla J, Kümpfel T, Schinner R, et al. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol. 2017;264(1):139–151.
   PubMed Web of Science ®Google Scholar
• Gass JD. Müller cell cone, an overlooked part of the anatomy of the fovea centralis: hypotheses concerning its role in the pathogenesis of macular hole and foveomacualr retinoschisis. Arch Ophthalmol. 1999;117(6):821–823.
   Google Scholar
• Daruich A, Matet A, Moulin A, et al. Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res. 2018;63:20–68.
   PubMed Web of Science ®Google Scholar
• Verkman AS, Smith AJ, Phuan PU-W, et al. The aquaporin-4 water channel as a potential drug target in neurological disorders. Expert Opin Ther Targets. 2017;21(12):1161–1170.
   PubMed Web of Science ®Google Scholar
• Filgueiras TG, Oyamada MK, Preti RC, et al. Outer retinal dysfunction on multifocal electroretinography may help differentiating multiple sclerosis from neuromyelitis optica spectrum disorder. Front Neurol. 2019;10:928.
   PubMedGoogle Scholar
• Filippatou AG, Vasileiou ES, He Y, et al. Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD. Mult Scler J. 2021;27(11):1738–1748
   Google Scholar
• Oertel FC, Havla J, Roca-Fernández A, et al. Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. J Neurol Neurosurg Psychiatry. 2018;89(12)1259–1265.
   PubMed Web of Science ®Google Scholar
• Chen Y, Shi C, Zhou L, et al. The Detection of Retina Microvascular Density in Subclinical Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders. Front Neurol. 2020;11:35.
   Google Scholar
• Roca-Fernández A, Oertel FC, Yeo T, et al. Foveal changes in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder are independent of optic neuritis and not overtly progressive. Eur J Neurol. 2021;28(7):2280–2293.
   PubMedGoogle Scholar
• Manogaran P, Traboulsee AL, Lange AP. Longitudinal study of retinal nerve fiber layer thickness and macular volume in patients with neuromyelitis optica spectrum disorder. J Neuro-Ophthalmol. 2016;36(4):363–368.
   PubMedGoogle Scholar
• Pisa M, Ratti F, Vabanesi M, et al. Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography. Mult Scler J. 2020;26(10):1197–1206.
   PubMedGoogle Scholar
• Oertel FC, Outteryck O, Knier B, et al. Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study. J Neuroinflammation. 2019;16(1):154.
   PubMedGoogle Scholar
• Specovius S, Zimmermann HG, Oertel FC, et al. Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). BMJ Open. 2020;10(10):e035397.
   Google Scholar
• Deschamps R, Gueguen A, Lecler A, et al. Acute idiopathic optic neuritis: not always benign. Eur J Neurol. 2018;25(11):1378–1383.
   PubMed Web of Science ®Google Scholar
• Song H, Zhou H, Yang M, et al. Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China. Br J Ophthalmol. 2019;103(6):831–836.
   PubMedGoogle Scholar
• Song H, Zhou H, Yang M, et al. Different Characteristics of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody-Seropositive Male Optic Neuritis in China. J Ophthalmol. Hindawi. 2019;2019:4015075.
   Google Scholar
• Gao C, Zhuo Z, Duan Y, et al. Structural and Functional Alterations in Visual Pathway After Optic Neuritis in MOG Antibody Disease: a Comparative Study With AQP4 Seropositive NMOSD. Front Neurol. 2021;12:673472.
   Google Scholar
• Jeong IH, Kim HJ, Kim NH, et al. Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder. J Neurol. 2016;263(7):1343–1348.
   PubMed Web of Science ®Google Scholar
• Motamedi S, Oertel FC, Yadav SK, et al. Altered fovea in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. Neurol Neuroimmunol neuroinflammation. 2020;7(5):e805.
   PubMedGoogle Scholar
• Kashani AH, Chen C, Gahm JK, et al. Optical coherence tomography angiography: A comprehensive review of current methods and clinical applications. Prog Retin Eye Res. 2017;60:66–100.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang Q, Thorell MR, et al. Swept-source OCT angiography of the retinal vasculature using intensity differentiation-based optical microangiography algorithms. Ophthalmic Surg Lasers Imaging Retina. 2014;45(5):382–389.
   PubMed Web of Science ®Google Scholar
• Wang L, Murphy O, Caldito NG, et al. Emerging Applications of Optical Coherence Tomography Angiography (OCTA) in neurological research. Eye Vis (Lond). 2018;5:11.
   Google Scholar
• Ferrara D, Waheed NK, Duker JS. Investigating the choriocapillaris and choroidal vasculature with new optical coherence tomography technologies. Prog Retin Eye Res. 2016;52:130–155.
   PubMed Web of Science ®Google Scholar
• Kwapong WR, Peng C, He Z, et al. Altered Macular Microvasculature in Neuromyelitis Optica Spectrum Disorders. Am J Ophthalmol. 2018;192:47–55.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhou L, ZhangBao J, et al. Peripapillary and parafoveal vascular network assessment by optical coherence tomography angiography in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. Br J Ophthalmol. 2019;103(6):789–796.
   PubMed Web of Science ®Google Scholar
• Kleerekooper I, Houston S, Dubis AM, et al. Optical Coherence Tomography Angiography (OCTA) in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Front Neurol. 2020;11:604049.
   PubMedGoogle Scholar
• Yu J, Huang Y, Wu K, et al. Alterations in the Retinal Vascular Network and Structure in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis: a Longitudinal OCTA Study. Ocul Immunol Inflamm. 2021;00:1–5.
   Google Scholar
• Green AJ, Cree BAC. Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. J Neurol Neurosurg Psychiatry. 2009;80(9):1002–1005.
   PubMedGoogle Scholar
• Joyal JS, Gantner ML, Smith LEH. Retinal energy demands control vascular supply of the retina in development and disease: the role of neuronal lipid and glucose metabolism. Prog Retin Eye Res. 2018;64:131–156.
   PubMedGoogle Scholar
• Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007;130(5):1194–1205.
   PubMedGoogle Scholar
• Hood DC, Odel JG, Winn BJ. The multifocal visual evoked potential. J Neuroophthalmol. 2003;23(4):279–289.
   Google Scholar
• Grover LK, Hood DC, Ghadiali Q, et al. A comparison of multifocal and conventional visual evoked potential techniques in patients with optic neuritis/multiple sclerosis. Doc Ophthalmol. 2008;117(2):121–128.
   PubMedGoogle Scholar
• Klistorner A, Fraser C, Garrick R, et al. Correlation between full-field and multifocal VEPs in optic neuritis. Doc Ophthalmol. 2008;116(1):19–27.
   PubMedGoogle Scholar
• Watanabe A, Matsushita T, Doi H, et al. Multimodality-evoked potential study of anti-aquaporin-4 antibody-positive and -negative multiple sclerosis patients. J Neurol Sci. 2009;281(1–2):34–40.
   PubMedGoogle Scholar
• Neto SP, Pinto LC, Alvarenga RMP. The Visual Evoked Potential in Idiopathic Inflammatory Demyelinating Diseases. Event-Related Potentials and Evoked Potentials. Epub 2017 Nov 29
   Google Scholar
• Vabanesi M, Pisa M, Guerrieri S, et al. In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis. Sci Rep. 2019;9(1):10371.
   PubMedGoogle Scholar
• Ringelstein M, Kleiter I, Ayzenberg I, et al. Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Mult Scler J. 2014;20(5):617–620.
   PubMedGoogle Scholar
• Ringelstein M, Harmel J, Zimmermann H, et al. Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. Neurology. 2020;94(4):e407–e418.
   PubMed Web of Science ®Google Scholar
• Kim NH, Kim HJ, Park CY, et al. Optical coherence tomography versus visual evoked potentials for detecting visual pathway abnormalities in patients with neuromyelitis optica spectrum disorder. J Clin Neurol. 2018;14(2):200–205.
   PubMedGoogle Scholar
• Liu X, Faes L, Kale AU, et al. A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: a systematic review and meta-analysis. Lancet Digit Heal. 2019;1(6):e271–e297.
   PubMedGoogle Scholar
• De Fauw J, Ledsam JR, Romera-Paredes B, et al. Clinically applicable deep learning for diagnosis and referral in retinal disease. Nat Med. 2018;24(9):1342–1350.
   PubMed Web of Science ®Google Scholar
• Milea D, Najjar RP, Jiang Z, et al. Artificial Intelligence to Detect Papilledema from Ocular Fundus Photographs. N Engl J Med. 2020;382(18):1687–1695.
   PubMedGoogle Scholar
• Biousse V, Newman NJ, Najjar RP, et al. Optic Disc Classification by Deep Learning versus Expert Neuro-Ophthalmologists. Ann Neurol. 2020;88(4):785–795.
   PubMedGoogle Scholar
• Fang L, Cunefare D, Wang C, et al. Automatic segmentation of nine retinal layer boundaries in OCT images of non-exudative AMD patients using deep learning and graph search. Biomed Opt Express. 2017;8(5):2732–2744.
   PubMed Web of Science ®Google Scholar
• Lee CS, Tyring AJ, Deruyter NP, et al. Deep-learning based, automated segmentation of macular edema in optical coherence tomography. Biomed Opt Express. 2017;8(7):3440–3448.
   PubMed Web of Science ®Google Scholar
• Roy AG, Conjeti S, Karri SPK, et al. ReLaynet: retinal layer and fluid segmentation of macular optical coherence tomography using fully convolutional networks. Biomed Opt Express. 2017;8(8):3627–3642.
   PubMed Web of Science ®Google Scholar
• Kermany DS, Goldbaum M, Cai W, et al. Identifying Medical Diagnoses and Treatable Diseases by Image-Based Deep Learning. Cell. 2018;172(5):1122–1131.
   PubMed Web of Science ®Google Scholar
• Lu W, Tong Y, Yu Y, et al. Deep learning-based automated classification of multi-categorical abnormalities from optical coherence tomography images. Transl Vis Sci Technol. 2018;7(6):41.
   Google Scholar
• Hwang DK, Hsu CC, Chang KJ, et al. Artificial intelligence-based decision-making for age-related macular degeneration. Theranostics. 2019;9(1):232–245.
   PubMed Web of Science ®Google Scholar
• Petzold A, Albrecht P, Balcer L, et al. Artificial intelligence extension of the OSCAR-IB criteria. Ann Clin Transl Neurol. 2021;8(7):1528–1542.
   Google Scholar
• Soloman JM, Paul F, Chien C, et al. A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course. Ther Adv Neurol Disord. 2021;14:17562864211014389.
   Google Scholar
• Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805–815.
   PubMed Web of Science ®Google Scholar
• Kuchling J, Paul F. Visualizing the Central Nervous System: imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Front Neurol. 2020;11:450.
   Google Scholar
• Geraldes R, Ciccarelli O, Barkhof F, et al. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat Rev Neurol. 2018;14(4):199–213.
   PubMed Web of Science ®Google Scholar
• Cacciaguerra L, Meani A, Mesaros S, et al. Brain and cord imaging features in neuromyelitis optica spectrum disorders. Ann Neurol. 2019;85(3):371–384.
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Calabrese M, et al. Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. Neurology. 2010;75(22):1988–1994.
   PubMed Web of Science ®Google Scholar
• Calabrese M, Oh MS, Favaretto A, et al. No MRI evidence of cortical lesions in neuromyelitis optica. Neurology. 2012;79(16):1671–1676.
   PubMedGoogle Scholar
• Matthews L, Marasco R, Jenkinson M, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology. 2013;80(14):1330–1337.
   PubMed Web of Science ®Google Scholar
• Juryńczyk M, Tackley G, Kong Y, et al. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry. 2017;88(2):132–136.
   PubMed Web of Science ®Google Scholar
• Cai MT, Zhang YX, Zheng Y, et al. Brain lesion distribution criteria distinguish demyelinating diseases in China. Ann Clin Transl Neurol. 2019;6(10):2048–2053.
   PubMed Web of Science ®Google Scholar
• Hyun JW, Huh SY, Shin HJ, et al. Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis. Mult Scler J. 2019;25(4):585–590.
   PubMedGoogle Scholar
• Sinnecker T, Dörr J, Pfueller CF, et al. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology. 2012;79(7):708–714.
   PubMed Web of Science ®Google Scholar
• Cai MT, Zheng Y, Shen CH, et al. Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder. Mult Scler J. 2021;27(6):871–882.
   PubMedGoogle Scholar
• Cortese R, Magnollay L, Tur C, et al. Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD. Neurology. 2018;90(14):e1183–e1190.
   PubMed Web of Science ®Google Scholar
• Sinnecker T, Clarke MA, Meier D, et al. Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. JAMA Neurol. 2019;76(12):1446–1456.
   PubMed Web of Science ®Google Scholar
• Maggi P, Absinta M, Grammatico M, et al. Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol. 2018;83(2):283–294.
   PubMed Web of Science ®Google Scholar
• Denève M, Biotti D, Patsoura S, et al. MRI features of demyelinating disease associated with anti-MOG antibodies in adults. J Neuroradiol. 2019;46(5):312–318.
   PubMed Web of Science ®Google Scholar
• Salama S, Khan M, Shanechi A, et al. MRI differences between MOG antibody disease and AQP4 NMOSD. Mult Scler J. 2020;26(14):1854–1865.
   PubMedGoogle Scholar
• Hickman SJ, Brierley CMH, Brex PA, et al. Continuing optic nerve atrophy following optic neuritis: a serial MRI study. Mult Scler. 2002;8(4):339–342.
   PubMedGoogle Scholar
• Manogaran P, Vavasour IM, Lange AP, et al. Quantifying visual pathway axonal and myelin loss in multiple sclerosis and neuromyelitis optica. NeuroImage Clin. 2016;11:743–750.
   PubMedGoogle Scholar
• Harrigan RL, Smith AK, Lyttle B, et al. Quantitative characterization of optic nerve atrophy in patients with multiple sclerosis. Mult Scler J - Exp Transl Clin. 2017;3:2055217317730097.
   Google Scholar
• Cabrera-Gómez JA, Quevedo-Sotolongo L, González-Quevedo A, et al. Brain magnetic resonance imaging findings in relapsing neuromyelitis optica. Mult Scler. 2007;13(2):186–192.
   PubMedGoogle Scholar
• Pula JH, Kattah JC, Keung B, et al. Longitudinally extensive optic neuritis in neuromyelitis optica spectrum disorder. J Neurol Sci. 2014;345(1–2):209–212.
   PubMed Web of Science ®Google Scholar
• Mealy MA, Whetstone A, Orman G, et al. Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis. J Neurol Sci. 2015;355(1–2):59–63.
   PubMed Web of Science ®Google Scholar
• Cacciaguerra L, Valsasina P, Mesaros S, et al. Spinal Cord Atrophy in Neuromyelitis Optica Spectrum Disorders Is Spatially Related to Cord Lesions and Disability. Radiology. 2020;297(1):154–163.
   PubMedGoogle Scholar
• Mariano R, Messina S, Roca-Fernandez A, et al. Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis. Brain. 2021;144(1):198–212.
   PubMedGoogle Scholar
• Ayzenberg I, Richter D, Henke E, et al.Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: a Cross-Sectional Study of 166 AQP4 Antibody-Seropositive Patients. Neurol Neuroimmunol neuroinflammation. 2021;8(3):e985.
   Google Scholar
• Asseyer S, Kuchling J, Gaetano L, et al. Ventral posterior nucleus volume is associated with neuropathic pain intensity in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2020;46:102579.
   PubMedGoogle Scholar
• Yonezu T, Ito S, Mori M, et al. Bright spotty lesions” on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Scler J. 2014;20(3):331–337.
   PubMed Web of Science ®Google Scholar
• Hyun JW, Kim SH, Jeong IH, et al. Bright spotty lesions on the spinal cord: an additional MRI indicator of neuromyelitis optica spectrum disorder? J Neurol Neurosurg Psychiatry. 2015;86(11):1280–1282.
   PubMed Web of Science ®Google Scholar
• Krampla W, Aboul-Enein F, Jecel J, et al. Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur Radiol. 2009;19(10):2535–2543.
   PubMed Web of Science ®Google Scholar
• Chien C, Brandt AU, Schmidt F, et al. MRI-based methods for spinal cord atrophy evaluation: a comparison of cervical cord cross-sectional area, cervical cord volume, and full spinal cord volume in patients with aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders. Am J Neuroradiol. 2018;39(7):1362–1368.
   PubMedGoogle Scholar
• Trebst C, Raab P, Voss EV, et al. Longitudinal extensive transverse myelitis-it’s not all neuromyelitis optica. Nat Rev Neurol. 2011;7(12):688–698.
   PubMedGoogle Scholar
• Kitley JL, Leite MI, George JS, et al. The differential diagnosis of longitudinally extensive transverse myelitis. Mult Scler J. 2012;18(3):271–285.
   PubMed Web of Science ®Google Scholar
• Flanagan EP, Krecke KN, Marsh RW, et al. Specific pattern of gadolinium enhancement in spondylotic myelopathy. Ann Neurol. 2014;76(1):54–65.
   PubMedGoogle Scholar
• Flanagan EP, Kaufmann TJ, Krecke KN, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol. 2016;79(3):437–447.
   PubMed Web of Science ®Google Scholar
• Kister I, Johnson E, Raz E, et al. Specific MRI findings help distinguish acute transverse myelitis of Neuromyelitis Optica from spinal cord infarction. Mult Scler Relat Disord. 2016;9:62–67.
   PubMedGoogle Scholar
• Fang B, McKeon A, Hinson SR, et al. Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol. 2016;73(11):1297–1307.
   PubMed Web of Science ®Google Scholar
• Flanagan EP, Hinson SR, Lennon VA, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol. 2017;81(2):298–309.
   PubMed Web of Science ®Google Scholar
• Kunchok A, Zekeridou A, McKeon A. Autoimmune glial fibrillary acidic protein astrocytopathy. Curr Opin Neurol. 2019;32(3):452–458.
   PubMedGoogle Scholar
• Wickel J, Chung HY, Kirchhof K, et al. Encephalitis with radial perivascular emphasis: not necessarily associated with GFAP antibodies. Neurol Neuroimmunol neuroinflammation. 2020;7(2):e670.
   Google Scholar
• Flanagan EP, Weinshenker BG, Krecke KN, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol. 2015;72(1):81–87.
   PubMed Web of Science ®Google Scholar
• Huh SY, Kim SH, Hyun JW, et al. Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders. Mult Scler J. 2017;23(3):413–419.
   PubMedGoogle Scholar
• Sato DK, Nakashima I, Takahashi T, et al. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology. 2013;80(24):2210–2216.
   PubMed Web of Science ®Google Scholar
• Hu H, You X, Ye J. Short transverse myelitis in Chinese patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2018;21:78–83.
   PubMedGoogle Scholar
• Mariotto S, Ferrari S, Monaco S, et al. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. J Neurol. 2017;264(12):2420–2430.
   PubMed Web of Science ®Google Scholar
• dos Passos GR, Oliveira LM, Da Costa BK, et al. MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder. Front Neurol. 2018;9:217.
   PubMedGoogle Scholar
• Mariano R, Messina S, Kumar K, et al. Comparison of Clinical Outcomes of Transverse Myelitis among Adults with Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease. JAMA Network Open. 2019;2(10):e1912732.
   PubMedGoogle Scholar
• Cai W, Tan S, Zhang L, et al. Linear lesions may assist early diagnosis of neuromyelitis optica and longitudinally extensive transverse myelitis, two subtypes of NMOSD. J Neurol Sci. 2016;360:88–93.
   PubMedGoogle Scholar
• van Pelt ED, Wong YYM, Ketelslegers IA, et al. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. Eur J Neurol. 2016;23(3):580–587.
   PubMed Web of Science ®Google Scholar
• Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies a comparative study. JAMA Neurol. 2014;71(3):276–283.
   Google Scholar
• Kremer S, Renard F, Achard S, et al., Use of advanced magnetic resonance imaging techniques in neuromyelitis optica spectrum disorder. JAMA Neurol. 2015;72(7):815–822.
   PubMedGoogle Scholar
• Liu Y, Wang J, Daams M, et al. Differential patterns of spinal cord and brain atrophy in NMO and MS. Neurology. 2015;84(14):1465–1472.
   PubMed Web of Science ®Google Scholar
• Liu Y, Fu Y, Schoonheim MM, et al. Structural MRI substrates of cognitive impairment in neuromyelitis optica. Neurology. 2015;85(17):1491–1499.
   PubMedGoogle Scholar
• Wang Q, Zhang N, Qin W, et al. Gray matter volume reduction is associated with cognitive impairment in neuromyelitis optica. Am J Neuroradiol. 2015;36(10):1822–1829.
   Google Scholar
• Matthews L, Kolind S, Brazier A, et al. Imaging surrogates of disease activity in neuromyelitis optica allow distinction from multiple sclerosis. PLoS One. 2015;10(9):e0137715.
   Google Scholar
• Finke C, Heine J, Pache F, et al. Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD. Neurol Neuroimmunol NeuroInflammation. 2016;3(3):e229.
   Google Scholar
• Hyun JW, Park G, Kwak K, et al. Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis. Eur J Neurol. 2017;24(2):437–445.
   PubMedGoogle Scholar
• Schneider R, Bellenberg B, Kleiter I, et al. Cervical cord and ventricle affection in neuromyelitis optica. Acta Neurol Scand. 2017;135(3):324–331.
   PubMedGoogle Scholar
• Schmidt FA, Chien C, Kuchling J, et al. Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: a Comparative Study. Front Neurol. 2020;11:499910.
   Google Scholar
• Papadopoulou A, Oertel FC, Gaetano L, et al. Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2019;90(10):1156–1164.
   PubMedGoogle Scholar
• Papadopoulou A, Oertel FC, Chien C, et al. Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: a longitudinal study. NeuroImage Clin. 2021;30:102608.
   PubMedGoogle Scholar
• Ventura RE, Kister I, Chung S, et al. Cervical spinal cord atrophy in nmosd without a history of myelitis or MRI-visible lesions. Neurol Neuroimmunol NeuroInflammation. 2016;3(3):e224.
   PubMedGoogle Scholar
• Kuchling J, Brandt AU, Paul F, et al. Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system. EPMA J. 2017;8(3):279–294.
   PubMedGoogle Scholar
• Assaf Y, Pasternak O. Diffusion tensor imaging (DTI)-based white matter mapping in brain research: a review. J Mol Neurosci. 2008;34(1):51–61.
   PubMed Web of Science ®Google Scholar
• Inglese M, Bester M. Diffusion imaging in multiple sclerosis: research and clinical implications. NMR Biomed. 2010;23(7):865–872.
   PubMed Web of Science ®Google Scholar
• Liu Y, Duan Y, He Y, et al. A tract-based diffusion study of cerebral white matter in neuromyelitis optica reveals widespread pathological alterations. Mult Scler J. 2012;18(7):1013–1021.
   PubMedGoogle Scholar
• Zhao DD, Zhou HY, Wu QZ, et al. Diffusion tensor imaging characterization of occult brain damage in relapsing neuromyelitis optica using 3.0T magnetic resonance imaging techniques. Neuroimage. 2012;59(4):3173–3177.
   PubMedGoogle Scholar
• Pichiecchio A, Tavazzi E, Poloni G, et al. Advanced magnetic resonance imaging of neuromyelitis optica: a multiparametric approach. Mult Scler J. 2012;18(6):817–824.
   PubMed Web of Science ®Google Scholar
• Lopes FCR, Doring T, Martins C, et al. The role of demyelination in neuromyelitis optica damage: diffusion-tensor MR imaging study. Radiology. 2012;263(1):235–242.
   PubMedGoogle Scholar
• Jeantroux J, Kremer S, Lin XZ, et al. Diffusion tensor imaging of normal-appearing white matter in neuromyelitis optica. J Neuroradiol. 2012;39(5):295–300.
   PubMedGoogle Scholar
• Doring TM, Lopes FCR, Kubo TTA, et al. Neuromyelitis optica: a diffusional kurtosis imaging study. Am J Neuroradiol. 2014;35(12):2287–2292.
   PubMedGoogle Scholar
• Kimura MCG, Doring TM, Rueda FC, et al. In vivo assessment of white matter damage in neuromyelitis optica: a diffusion tensor and diffusion kurtosis MR imaging study. J Neurol Sci. 2014;345(1–2):172–175.
   PubMedGoogle Scholar
• Pache F, Zimmermann H, Finke C, et al. Brain parenchymal damage in neuromyelitis optica spectrum disorder – a multimodal MRI study. Eur Radiol. 2016;26(12):4413–4422.
   PubMed Web of Science ®Google Scholar
• Kuchling J, Backner Y, Oertel FC, et al. Comparison of probabilistic tractography and tract-based spatial statistics for assessing optic radiation damage in patients with autoimmune inflammatory disorders of the central nervous system. NeuroImage Clin. 2018;19:538–550.
   PubMed Web of Science ®Google Scholar
• Lopes FCR, Alves-Leon SV, Godoy JM, et al. Optic Neuritis and the Visual Pathway: evaluation of Neuromyelitis Optica Spectrum by Resting-State fMRI and Diffusion Tensor MRI. J Neuroimaging. 2015;25(5):807–812.
   PubMedGoogle Scholar
• Cai H, Zhu J, Zhang N, et al. Subregional structural and connectivity damage in the visual cortex in neuromyelitis optica. Sci Rep. 2017;7:41914.
   Google Scholar
• Finke C, Zimmermann H, Pache F, et al. Association of visual impairment in neuromyelitis optica spectrum disorder with visual network reorganization. JAMA Neurol. 2018;75(3):296–303.
   PubMedGoogle Scholar
• Bigaut K, Achard S, Hemmert C, et al. Resting-state functional MRI demonstrates brain network reorganization in neuromyelitis optica spectrum disorder (NMOSD). PLoS One. 2019;14(1):e0211465.
   PubMedGoogle Scholar
• Rocca MA, Savoldi F, Valsasina P, et al. Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders. Mult Scler J. 2019;25(7):968–979.
   PubMedGoogle Scholar
• Backner Y, Ben-Shalom I, Kuchling J, et al. Cortical topological network changes following optic neuritis. Neurol Neuroimmunol neuroinflammation. 2020;7(3):e687.
   PubMedGoogle Scholar
• Sun M, Zhou H, Xu Q, et al. Differential patterns of interhemispheric functional connectivity between AQP4-optic neuritis and MOG-optic neuritis: a resting-state functional MRI study. Acta Radiol. 2021;62(6):776–783.
   PubMedGoogle Scholar
• von Glehn F, Jarius S, Cavalcanti Lira RP, et al. Structural brain abnormalities are related to retinal nerve fiber layer thinning and disease duration in neuromyelitis optica spectrum disorders. Mult Scler J. 2014;20(9):1189–1197.
   PubMedGoogle Scholar
• Chien C, Oertel FC, Siebert N, et al. Imaging markers of disability in aquaporin-4 immunoglobulin G seropositive neuromyelitis optica: a graph theory study. Brain Commun. 2019;1(1):fcz026.
   PubMedGoogle Scholar
• Gabilondo I, Martínez-Lapiscina EH, Fraga-Pumar E, et al. Dynamics of retinal injury after acute optic neuritis. Ann Neurol. 2015;77(3):517–528.
   PubMed Web of Science ®Google Scholar
• Raz N, Bick AS, Ben-Hur T, et al. Focal demyelinative damage and neighboring white matter integrity: an optic neuritis study. Mult Scler J. 2015;21(5):562–571.
   PubMedGoogle Scholar
• Sinnecker T, Oberwahrenbrock T, Metz I, et al. Optic radiation damage in multiple sclerosis is associated with visual dysfunction and retinal thinning – an ultrahigh-field MR pilot study. Eur Radiol. 2015;25(1):122–131.
   PubMedGoogle Scholar
• Tian DC, Su L, Fan M, et al. Bidirectional degeneration in the visual pathway in neuromyelitis optica spectrum disorder (NMOSD). Mult Scler J. 2018;24(12):1585–1593.
   PubMedGoogle Scholar
• Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019;381(7):614–625.
   PubMed Web of Science ®Google Scholar
• Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019;381(22):2114–2124.
   PubMed Web of Science ®Google Scholar
• Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402–412.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang M, Qiu W, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391–401.
   PubMed Web of Science ®Google Scholar
• Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352–1363.
   PubMed Web of Science ®Google Scholar
• Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298–306.
   PubMed Web of Science ®Google Scholar
• Nikoo Z, Badihian S, Shaygannejad V, et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol. 2017;264(9):2003–2009.
   PubMed Web of Science ®Google Scholar
• Valencia-Sanchez C, Wingerchuk DM. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders. BioDrugs. 2021;35(1):7–17.
   PubMedGoogle Scholar
• Xue T, Yu J, Chen S, et al. Different Targets of Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders: a Meta-Analysis Evidenced From Randomized Controlled Trials. Front Neurol. 2020;11:604445.
   Google Scholar
• Sühs KW, Hein K, Sättler MB, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol. 2012;72(2):199–210.
   PubMed Web of Science ®Google Scholar
• Diem R, Molnar F, Beisse F, et al. Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol. BMJ Open. 2016;6(3):e010956.
   PubMedGoogle Scholar
• Tintore M, Rovira À, Río J, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015;138(7):1863–1874.
   PubMed Web of Science ®Google Scholar
• Zimmermann HG, Knier B, Oberwahrenbrock T, et al. Association of retinal ganglion cell layer thickness with future disease activity in patients with clinically isolated syndrome. JAMA Neurol. 2018;75(9):1071–1079.
   PubMed Web of Science ®Google Scholar
• Lin TY, Vitkova V, Asseyer S, et al. Increased serum neurofilament light and thin ganglion cell-inner plexiform layer are additive risk factors for disease activity in early MS. Neurol Neuroimmunol neuroinflammation. 2021;8(5):e1051.
   PubMed Web of Science ®Google Scholar